Characteristics of proton pump inhibitor‐resistant severe reflux esophagitis and efficacy of vonoprazan in elderly (older than 75 years) and non‐elderly groups
Shintaro Hoshino,
Eri Momma,
Rina Motomiya,
Tomohide Tanabe,
Mai Koeda,
Yoshimasa Hoshikawa,
Noriyuki Kawami,
Katsuhiko Iwakiri
Affiliations
Shintaro Hoshino
Department of Gastroenterology, Nippon Medical School Graduate School of Medicine Bunkyo‐ku Tokyo Japan
Eri Momma
Department of Gastroenterology, Nippon Medical School Graduate School of Medicine Bunkyo‐ku Tokyo Japan
Rina Motomiya
Department of Gastroenterology, Nippon Medical School Graduate School of Medicine Bunkyo‐ku Tokyo Japan
Tomohide Tanabe
Department of Gastroenterology, Nippon Medical School Graduate School of Medicine Bunkyo‐ku Tokyo Japan
Mai Koeda
Department of Gastroenterology, Nippon Medical School Graduate School of Medicine Bunkyo‐ku Tokyo Japan
Yoshimasa Hoshikawa
Department of Gastroenterology, Nippon Medical School Graduate School of Medicine Bunkyo‐ku Tokyo Japan
Noriyuki Kawami
Department of Gastroenterology, Nippon Medical School Graduate School of Medicine Bunkyo‐ku Tokyo Japan
Katsuhiko Iwakiri
Department of Gastroenterology, Nippon Medical School Graduate School of Medicine Bunkyo‐ku Tokyo Japan
Abstract Background and Aim Previous studies on age differences in proton pump inhibitor (PPI)‐resistant reflux esophagitis (RE) have found that stenosis and bleeding complications were significantly more common in the elderly than in the non‐elderly. We sought to examine differences between two groups of elderly (75 years or older) and non‐elderly (4 cm) was significantly higher in the elderly group, while significantly more non‐elderly patients had collagen disease. In the non‐elderly group with scleroderma, the efficacy of VPZ 20 mg may not be sufficient.
